弥散加权MRI预测乳腺癌新辅助化疗早期反应的价值:ROI-ADC与全病灶-ADC测量的比较
该前瞻性单中心研究纳入55例乳腺癌患者,在治疗前、1周期新辅助化疗后及新辅助化疗完成后行MRI,比较ROI-ADC与全病灶-ADC测量对病理完全缓解和影像学完全缓解的预测价值。结果显示,1周期后ROI-ADC较基线增加超过47.5%预测病理完全缓解的敏感度为88.9%、特异度为63.4%,全病灶-ADC未能预测病理完全缓解。
要点
- 1周期新辅助化疗后ROI-ADC较基线增加超过47.5%可预测病理完全缓解(敏感度88.9%,特异度63.4%)。
- ROI-ADC增加超过47.5%预测影像学完全缓解的敏感度为83.3%、特异度为64.9%。
- 全病灶-ADC增加超过25.5%预测影像学完全缓解的敏感度为83.3%、特异度为75.5%,但未预测病理完全缓解。
核心结论
- 1周期新辅助化疗后,乳腺肿瘤ROI-ADC在DWI上显著增加可预测病理完全缓解和影像学完全缓解。
研究设计与样本
- 前瞻性单中心研究,2016年1月至2019年12月纳入55例女性,最终48例纳入分析;每个患者在治疗前(MRI 1:DWI和动态增强MRI)、1周期新辅助化疗后(MRI 2:平扫DWI)、新辅助化疗完成术前(MRI 3:DWI和动态增强MRI)三个时间点行MRI;ROI-ADC和全病灶-ADC测量与组织学结果及RCB分级比较,患者分为病理完全缓解与非病理完全缓解。
关键影像表现/征象
- ROI-ADC在MRI 1与MRI 2之间的增加超过47.5%预测病理完全缓解的敏感度为88.9%、特异度为63.4%。
- ROI-ADC在MRI 1与MRI 2之间的增加超过47.5%预测影像学完全缓解的敏感度为83.3%、特异度为64.9%。
- 全病灶-ADC在MRI 1与MRI 2之间的增加超过25.5%预测影像学完全缓解的敏感度为83.3%、特异度为75.5%。
- 全病灶-ADC未预测病理完全缓解。
诊断标准与关键数值
- ROI-ADC在MRI 1与MRI 2之间的增加超过47.5%预测病理完全缓解:敏感度88.9%,特异度63.4%。
- ROI-ADC在MRI 1与MRI 2之间的增加超过47.5%预测影像学完全缓解:敏感度83.3%,特异度64.9%。
- 全病灶-ADC在MRI 1与MRI 2之间的增加超过25.5%预测影像学完全缓解:敏感度83.3%,特异度75.5%。
临床应用与阅片要点
- 1周期新辅助化疗后行平扫DWI测量ROI-ADC,较基线增加超过47.5%提示可能达到病理完全缓解和影像学完全缓解。
- 全病灶-ADC增加超过25.5%提示可能达到影像学完全缓解,但全病灶-ADC未预测病理完全缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of the study was to assess DWI with ROI-ADC and WL-ADC measurements in early response after NAC in breast cancer.
METHODS: Between January 2016 and December 2019, 55 women were enrolled in this prospective single-center study. MRI was performed at three time points for each patient: before treatment (MRI 1: DW and DCE MRI), after one cycle of NAC (MRI 2: noncontrast DW MRI), and after completion of NAC before surgery (MRI 3: DW and DCE MRI). ROI-ADC and WL-ADC measurements were obtained on MRI and were compared to histology findings and to the RCB class. Patients were categorized as having pCR or non-pCR.
RESULTS: Among 48 patients, 9 experienced pCR. An increase of ROI-ADC between MRI 1 and 2 of more than 47.5% had a sensitivity of 88.9% and a specificity of 63.4% in predicting pCR, whereas WL-ADC did not predict pCR. An increase of ROI-ADC between MRI 1 and 2 of more than 47.5% had a sensitivity of 83.3% and a specificity of 64.9% in predicting radiologic complete response. An increase of WL-ADC between MRI 1 and 2 of more than 25.5% had a sensitivity of 83.3% and a specificity of 75.5% in predicting radiologic complete response.
CONCLUSION: After one cycle of NAC, a significant increase in breast tumor ROI-ADC at DWI predicted complete pathologic and radiologic responses.
KEY POINTS: • An increase of WL-ADC between MRI 1 and 2 of more than 25.5% had a sensitivity of 83.3% and a specificity of 75.5% in predicting radiologic complete response. • An increase of ROI-ADC between MRI 1 and 2 of more than 47.5% had a sensitivity of 88.9% and a specificity of 63.4% in predicting pCR, and a sensitivity of 83.3% and a specificity of 64.9% in predicting radiologic complete response. • A significant increase in breast tumor ROI-ADC at DWI predicted complete pathologic and radiologic responses.
引用
- Hottat, Badr, Lecomte, et al. Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements. Eur Radiol. 2022. PMID: 35015127. doi:10.1007/s00330-021-08462-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。